Cargando…
The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß‐catenin signaling
BACKGROUND: To date, no biomarkers exist to predict response or resistance to immunotherapy in hepatocellular carcinoma (HCC). Recent approaches to classify HCC into different immunological states revealed a negative correlation between Wnt/ß‐catenin activation and immunogenicity and T‐cell infiltra...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955077/ https://www.ncbi.nlm.nih.gov/pubmed/34309225 http://dx.doi.org/10.1002/cnr2.1493 |